drugset / Trial / NCT06416085

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

NCT06416085 ↗

Phase 2 Active not recruiting 15 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelSupportive care

Summary

The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.

Timeline

Start
2024-06-06
Primary completion
2026-12-15
Completion
2026-12-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral